Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NewAmsterdam Pharma (NAMS) Depreciation & Amortization (CF) (2023 - 2025)

NewAmsterdam Pharma's Depreciation & Amortization (CF) history spans 3 years, with the latest figure at $59000.0 for Q4 2025.

  • For Q4 2025, Depreciation & Amortization (CF) rose 15.69% year-over-year to $59000.0; the TTM value through Dec 2025 reached $220000.0, up 94.69%, while the annual FY2025 figure was $220000.0, 94.69% up from the prior year.
  • Depreciation & Amortization (CF) for Q4 2025 was $59000.0 at NewAmsterdam Pharma, down from $64000.0 in the prior quarter.
  • Across five years, Depreciation & Amortization (CF) topped out at $64000.0 in Q3 2025 and bottomed at $9000.0 in Q1 2023.
  • The 3-year median for Depreciation & Amortization (CF) is $23500.0 (2024), against an average of $31833.3.
  • The largest annual shift saw Depreciation & Amortization (CF) surged 292.31% in 2024 before it grew 15.69% in 2025.
  • A 3-year view of Depreciation & Amortization (CF) shows it stood at $13000.0 in 2023, then soared by 292.31% to $51000.0 in 2024, then increased by 15.69% to $59000.0 in 2025.
  • Per Business Quant, the three most recent readings for NAMS's Depreciation & Amortization (CF) are $59000.0 (Q4 2025), $64000.0 (Q3 2025), and $45000.0 (Q2 2025).